Get the Stockscreener App
2.75
2.23%
0.06
Onkure Therapeutics Inc stock is traded at $2.75, with a volume of 20,763.
It is up +2.23% in the last 24 hours and up +27.31% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
See More
Previous Close:
$2.69
Open:
$2.68
24h Volume:
20,763
Relative Volume:
0.24
Market Cap:
$35.32M
Revenue:
-
Net Income/Loss:
$-70.20M
P/E Ratio:
-0.0614
EPS:
-44.82
Net Cash Flow:
$-50.66M
1W Performance:
+0.00%
1M Performance:
+27.31%
6M Performance:
-46.39%
1Y Performance:
+0.00%
1-Day Range:
$2.6109
$2.75
1-Week Range:
$2.55
$2.975
52-Week Range:
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.75 | 36.40M | 0 | -70.20M | -50.66M | -44.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
What to expect from OnKure Therapeutics Inc. in the next 30 days2025 Trading Volume Trends & Accurate Entry/Exit Alerts - Newser
Key metrics from OnKure Therapeutics Inc.’s quarterly dataWeekly Trade Summary & Technical Pattern Based Signals - Newser
Strategies to average down on OnKure Therapeutics Inc.Market Performance Summary & Risk Controlled Swing Alerts - Newser
Using economic indicators to assess OnKure Therapeutics Inc. potentialSwing Trade & Risk Managed Investment Strategies - Newser
Real time alert setup for OnKure Therapeutics Inc. performance2025 Dividend Review & Community Supported Trade Ideas - Newser
How to build a custom watchlist for OnKure Therapeutics Inc.Weekly Trend Summary & AI Driven Price Predictions - Newser
Is OnKure Therapeutics Inc. still worth holding after the dipTreasury Yields & Advanced Swing Trade Entry Alerts - Newser
What to do if you’re stuck in OnKure Therapeutics Inc.Quarterly Profit Review & Technical Pattern Recognition Alerts - Newser
Has OnKure Therapeutics Inc. formed a bullish divergence2025 Key Highlights & Community Verified Swing Trade Signals - Newser
Is a relief rally coming for OnKure Therapeutics Inc. holdersMarket Risk Report & Free Reliable Trade Execution Plans - Newser
How to build a dashboard for OnKure Therapeutics Inc. stock2025 Valuation Update & Long-Term Growth Stock Strategies - Newser
Can OnKure Therapeutics Inc. expand into new marketsWeekly Investment Recap & Reliable Volume Spike Trade Alerts - خودرو بانک
How to track smart money flows in OnKure Therapeutics Inc.July 2025 Snapshot & AI Enhanced Market Trend Forecasts - Newser
How sensitive is OnKure Therapeutics Inc. to inflation2025 Buyback Activity & Risk Controlled Daily Plans - خودرو بانک
Using RSI to spot recovery in OnKure Therapeutics Inc.Weekly Stock Analysis & Daily Growth Stock Investment Tips - Newser
Can OnKure Therapeutics Inc. hit a new high this monthJuly 2025 Short Interest & Consistent Income Trade Recommendations - Newser
Is OnKure Therapeutics Inc. stock bottoming outTrade Volume Report & Reliable Intraday Trade Alerts - Newser
Building trade automation scripts for OnKure Therapeutics Inc.Volume Spike & Free Daily Entry Point Trade Alerts - Newser
Screener Results Flag OnKure Therapeutics Inc. as Oversold2025 Year in Review & Weekly Stock Performance Updates - beatles.ru
Market reaction to OnKure Therapeutics Inc.’s recent newsTrade Analysis Report & Consistent Profit Focused Trading Strategies - Newser
Published on: 2025-09-04 06:05:03 - Newser
What does recent volatility data suggest for OnKure Therapeutics Inc.Earnings Recap Summary & Fast Entry High Yield Tips - Newser
What moving averages say about OnKure Therapeutics Inc.Quarterly Earnings Report & Real-Time Volume Analysis - Newser
How sentiment analysis helps forecast OnKure Therapeutics Inc.2025 Trade Ideas & Scalable Portfolio Growth Ideas - Newser
Developing predictive dashboards with OnKure Therapeutics Inc. dataEarnings Summary Report & AI Driven Price Predictions - Newser
Is OnKure Therapeutics Inc. impacted by rising ratesEarnings Risk Report & Low Risk High Win Rate Stock Picks - خودرو بانک
What’s the MACD signal for OnKure Therapeutics Inc.2025 Risk Factors & Real-Time Chart Breakout Alerts - خودرو بانک
When is the best time to exit OnKure Therapeutics Inc.Trade Entry Report & Reliable Price Action Trade Plans - Newser
Published on: 2025-09-03 07:13:09 - Newser
OnKure Therapeutics Inc. stock daily chart insightsJuly 2025 Update & High Yield Stock Recommendations - Newser
OnKure Therapeutics Inc. recovery potential after sell offPortfolio Risk Report & Safe Entry Zone Tips - Newser
Leading vs lagging indicators on OnKure Therapeutics Inc. performanceEarnings Overview Summary & Advanced Technical Signal Analysis - Newser
Using data models to predict OnKure Therapeutics Inc. stock movementWeekly Risk Summary & Precise Trade Entry Recommendations - Newser
Is OnKure Therapeutics Inc. a strong growth stockQuarterly Profit Report & Technical Buy Zone Confirmations - خودرو بانک
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Onkure Therapeutics Inc Stock (OKUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
| Leverone Jason A. | Chief Financial Officer |
Apr 04 '25 |
Sale |
3.33 |
1,278 |
4,253 |
15,053 |
| Leonard Braden Michael | 10% Owner |
Sep 25 '24 |
Buy |
1.50 |
68,746 |
102,872 |
3,457,395 |
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):